Rest activation and lithium salt administration for the treatment of neurological disorders

Lithium orotate and REST activation therapies address the molecular mechanisms of neuronal resilience, enhancing therapeutic outcomes for neurological and psychiatric disorders by increasing REST levels and reducing toxic side effects.

WO2026024717A1 Publication Date: 2026-01-29PRESIDENT & FELLOWS OF HARVARD COLLEGE +1
1 Cites 0 Cited by

Patent Information

Application Number
PCT/US2025/038655
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-07-22
Filing Date
2025-07-22
Publication Date
2026-01-29

AI Technical Summary

Technical Problem

Current treatments for neurological and psychiatric disorders, such as Alzheimer's disease and bipolar disorder, lack a clear molecular mechanism for neuronal resilience and are limited by the toxic effects of lithium salts like lithium carbonate, and existing therapies fail to effectively address early structural brain abnormalities and gene-environment interactions.

Method used

The use of lithium orotate and REST activation therapies, combined with additional treatments like anti-Tau or anti-amyloid therapies, to increase REST expression or activity in the central nervous system, thereby treating or preventing neurological and psychiatric disorders.

Benefits of technology

Enhances neuronal resilience and reduces the risk of cognitive decline by increasing REST levels, providing therapeutic benefits for neurodegenerative and psychiatric disorders, including Alzheimer's disease and bipolar disorder, while minimizing toxic side effects.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Provided herein are methods and compositions for treating neurological diseases (e.g., neurodegenerative disorders (e.g., Alzheimer's disease, Parkinson's disease, dementia, a tauopathy, chronic traumatic encephalopathy (CTE), traumatic brain injury (TBI), mild cognitive impairment); psychiatric disorders (e.g., bipolar disorder, schizophrenia, depression, anxiety, post-traumatic stress disorder, obsessive compulsive disorder); inflammation in the central nervous system) using lithium salts, activators that increase the expression or activity of the RE1 silencing transcription factor (REST), or a combination thereof, or in combination with an additional agent.
Need to check novelty before this filing date? Find Prior Art